The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia - The lipid lowering effect of anagliptin in type2 diabetes mellitus with dyslipidemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013682

Enrollment

Registered

2014-04-18

Start date

2014-04-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 diabetes mellitus patients with dyslipidemia

Interventions

anagliptin as a suiny tablet.Taking a dose of 100 to 200 mg twice a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type2 diabetes mellitus patients who accords the terms below. 1.Patients whose LDL-C between 100mg/dL to 160mg/dL with or without taking drugs for dyslipidemia. 2.Patients whose treatment for diabetes mellitus will not change between the trial periods. 3.Written informed consent is obtained from subjects before entry. 4.Patients who is over 20years old.

Exclusion criteria

Exclusion criteria: 1.Patients who accord the contraindication of anagliptin. 2.Patients whose HbA1c over 8.0% before entry. 3.Patients who suffered coronary heart disease in past. 4.Patients whose renal function is declined (Ccr below the 30) or ongoing dialysis. 5.Individuals who are ineligible in the opinion of the physician in charge.

Design outcomes

Secondary

Measure	Time frame
Change of serum lipids and apolipoproteins	—

Primary

Measure	Time frame
Change of sitosterol, campesterol and lathosterol	—

Countries

Japan

Contacts

Public ContactMitsunobu Kawamura

Tokyo Teishin Hospital Internal Medicine

mk-hakodate@tth-japanpost.jp03-5214-7111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026